A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks in Subjects With Chronic HCV
Latest Information Update: 09 May 2023
Price :
$35 *
At a glance
- Drugs Sofosbuvir/velpatasvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms ASTRAL-1
- Sponsors Gilead Sciences
- 01 May 2023 Results of pooled analysis (n=1151) assessing the safety and tolerability of sofosbuvir/velpatasvir for the treatment of hepatitis C virus infection in three Phase 3 registrational studies (ASTRAL-1, NCT02201940; ASTRAL-2, NCT02220998; ASTRAL-3, NCT02201953) in patients with and without compensated cirrhosis, published in the Journal of Viral Hepatitis.
- 08 Nov 2022 Results of post-hoc analysis of Phase 3 trials with SOF/VEL 12 weeks without ribavirin (RBV) (ASTRAL 1-5, and POLARIS4) presented at The Liver Meeting 2022: 73rd Annual Meeting of the American Association for the Study of Liver Diseases
- 01 Oct 2018 Results of a pooled analysis assessing patients reported outcomes from 11 studies, published in the Value in Health.